Alumis Inc. is a clinical-stage biopharmaceutical company. The Company is developing oral therapies using a precision approach to optimize clinical outcomes and significantly improve the lives of patients with immune-mediated diseases. It builds a pipeline of molecules with the potential to address a range of immune-mediated diseases, such as monotherapy or combination therapies. It is focused on developing its two Tyrosine Kinase 2 (TYK2) inhibitors: ESK-001, a second-generation inhibitor that it is developing to maximize target inhibition and optimize tolerability, and A-005, a central nervous system (CNS) penetrant molecule. Its ESK-001 is an oral, highly selective, small molecule, allosteric inhibitor of tyrosine kinase 2 that is being evaluated for the treatment of patients with moderate-to-severe plaque psoriasis and systemic lupus erythematosus. A-005, a CNS-penetrant, allosteric TYK2 inhibitor for the treatment of neuroinflammatory and neurodegenerative diseases.